Nine Square Therapeutics
New York
About Nine Square Therapeutics
Nine Square Therapeutics is discovering new small-molecule therapeutics for degenerative movement disorders including Parkinson’s disease and amyotrophic lateral sclerosis (ALS), as well as non-degenerative disorders such as essential tremor and dyskinesias, by integrating computational chemistry, biophysics, and computational biology into machine-learning-enabled cell profiling platforms for target identification, chemical optimization, and patient stratification. It was founded in 2020 and headquartered in New York, United States.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $54.5M
- Funding stage: Early Stage Venture
- Last round: Grant (Sep 2023)
- Website: ninesquaretx.com
Industries & Categories
Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/nine-square-therapeutics-104136 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.